tirzepatide gray market the weight loss drug everyone is asking about isn't FDA approved yet. retatrutide. triple agonist. GLP-1 + GIP + glucagon. phase 3 data showing ~29% body weight reduction. people are already sourcing I ran the math on

Age, body weight, kidney function, and liver health all modify the theoretical seven-day half-life in real-world patients

Prefer the fastest route

Based on early human studies and animal research, GLP-1 agonists may affect: Reward-related eating behaviours by potentially modulating dopamine signalling in brain reward circuits Food cravings and hedonic eating (eating for pleasure rather than hunger) Impulsivity around food , possibly reducing the compulsive aspects of eating Satiety signalling , enhancing the feeling of fullness after meals Some patients using GLP-1 medications for diabetes or weight management report not just reduced appetite but also diminished preoccupation with food, fewer intrusive thoughts about eating, and reduced cravings for specific foods, particularly those high in fat and sugar

Payments: Patients will pay a $50 co-payment monthly, with government covering the remaining costs